Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
Ningke Hou, Lei Shuai, Lijing Zhang, et al.
ACS Central Science (2023) Vol. 9, Iss. 2, pp. 217-227
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Structural biology of SARS-CoV-2 Mpro and drug discovery
Yinkai Duan, Haofeng Wang, Zhenghong Yuan, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102667-102667
Closed Access | Times Cited: 22
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Lijing Zhang, Xuping Xie, Hannan Luo, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Evolution of chemistry and selection technology for DNA-encoded library
Peixiang Ma, Shuning Zhang, Qianping Huang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 492-516
Open Access | Times Cited: 19
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 15
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 6
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 844-844
Open Access | Times Cited: 5
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening
Hengrui Liu, Arie Zask, F. Forouhar, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Optimization of SARS-CoV-2 Mpro Inhibitors by a Structure-Based Multilevel Virtual Screening Method
Lanlan Jing, Fabao Zhao, Lin Zheng, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 670-670
Open Access
The Chiral 5,6-Cyclohexane-fused Uracil Ring-System: a Molecular Platform with Promising Activity against SARS-CoV-2
Enrico Marcantonio, Debora Guazzetti, Crescenzo Coppa, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117302-117302
Closed Access
Identifying Inhibitor-SARS-CoV2-3CLpro Binding Mechanism Through Molecular Docking, GaMD Simulations, Correlation Network Analysis and MM-GBSA Calculations
Jianzhong Chen, Jian Wang, Wanchun Yang, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 805-805
Open Access
Affinity-based DEL Selections with Different Target Types: Overview and Achievements
Qiuxia Chen, David I. Israel
Royal Society of Chemistry eBooks (2025), pp. 1-16
Closed Access
Design, synthesis and activity evaluation of 4-(quinoline-2-yl)aniline derivatives as SARS-CoV‑2 main protease inhibitors
Honglei Bao, Hui Meng, Shilin Gong, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 121, pp. 118135-118135
Closed Access
Discovery of a Potent and in Vivo Anti-inflammatory Efficacious, P2Y14R Antagonist with a Novel Benzisoxazoles Scaffold by DNA-Encoded Chemical Library Technology
Zhiyi Wei, Bingqian Han, Longhua Yang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117451-117451
Closed Access
Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses
Shulei Hu, Qiuyu Zhong, Xiong Xie, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130168-130168
Closed Access
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
Pengxuan Ren, Hui Li, Tianqing Nie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12266-12283
Closed Access | Times Cited: 13
Myocardial Oedema as a Consequence of Viral Infection and Persistence—A Narrative Review with Focus on COVID-19 and Post COVID Sequelae
N Panagiotides, Michael Poledniczek, Martin Andreas, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 121-121
Open Access | Times Cited: 4
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate
Zhidong Jiang, Bo Feng, Lu Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12760-12783
Closed Access | Times Cited: 4
Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CLpro) using deep learning
Prejwal Prabhakaran, Ananda Vardhan Hebbani, Soumya V. Menon, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 10
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
Jimena Pérez‐Vargas, L.J. Worrall, Andrea Olmstead, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top